BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Galafold (Migalastat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Galafold (Migalastat)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04020055-912@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT04020055)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and R
 enal Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04020055
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904261-912@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT06904261)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease an
 d Amenable GLA Variants\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06904261
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
